{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:56:53Z","timestamp":1785790613056,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-024-00859-1","type":"journal-article","created":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T02:01:56Z","timestamp":1710727316000},"page":"419-424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Additional renoprotective effect of the SGLT2 inhibitor dapagliflozin in a patient with ADPKD receiving tolvaptan treatment"],"prefix":"10.1007","volume":"13","author":[{"given":"Shun","family":"Minatoguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehisa","family":"Koide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotake","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"key":"859_CR1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"R-U M\u00fcller","year":"2022","unstructured":"M\u00fcller R-U, Messchendorp AL, Birn H, Capasso G, Cornec-Le Gall E, Devuyst O, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA working group on inherited kidney disorders, the European rare kidney disease reference network and polycystic kidney disease international. Nephrol Dial Transplant. 2022;37:825\u201339.","journal-title":"Nephrol Dial Transplant"},{"key":"859_CR2","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"859_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"859_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","journal-title":"N Engl J Med"},{"key":"859_CR5","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/ckj\/sfac029","volume":"15","author":"B Afsar","year":"2022","unstructured":"Afsar B, Afsar RE, Demiray A, Altay S, Korkmaz H, Yildiz A, et al. Sodium\u2013glucose cotransporter inhibition in polycystic kidney disease: fact or fiction. Clin Kidney J. 2022;15:1275\u201383.","journal-title":"Clin Kidney J"},{"key":"859_CR6","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.34067\/KID.0007422020","volume":"2","author":"DM Patel","year":"2021","unstructured":"Patel DM, Dahl NK. Examining the role of novel CKD therapies for the ADPKD patient. Kidney360. 2021;2:1036\u201341.","journal-title":"Kidney360"},{"key":"859_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196341","author":"F Morioka","year":"2023","unstructured":"Morioka F, Nakatani S, Uedono H, Tsuda A, Mori K, Emoto M. Short-term dapagliflozin administration in autosomal dominant polycystic kidney disease-a retrospective single-arm case series study. J Clin Med Res. 2023. https:\/\/doi.org\/10.3390\/jcm12196341.","journal-title":"J Clin Med Res"},{"key":"859_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-023-00840-4","author":"S Nakatani","year":"2023","unstructured":"Nakatani S, Morioka F, Uedono H, Tsuda A, Mori K, Emoto M. Dapagliflozin administration for 1 year promoted kidney enlargement in patient with ADPKD. CEN Case Rep. 2023. https:\/\/doi.org\/10.1007\/s13730-023-00840-4.","journal-title":"CEN Case Rep"},{"key":"859_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26:160.","journal-title":"J Am Soc Nephrol"},{"key":"859_CR10","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","volume":"371","author":"RW Schrier","year":"2014","unstructured":"Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371:2255\u201366.","journal-title":"N Engl J Med"},{"key":"859_CR11","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.kint.2018.12.023","volume":"95","author":"ASL Yu","year":"2019","unstructured":"Yu ASL, Shen C, Landsittel DP, Grantham JJ, Cook LT, Torres VE, et al. Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney Int. 2019;95:1253\u201361.","journal-title":"Kidney Int"},{"key":"859_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1681\/ASN.2007060688","volume":"19","author":"X Wang","year":"2008","unstructured":"Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19:102\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"859_CR13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2215\/CJN.04560510","volume":"6","author":"E Meijer","year":"2011","unstructured":"Meijer E, Bakker SJL, van der Jagt EJ, Navis G, de Jong PE, Struck J, et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6:361.","journal-title":"Clin J Am Soc Nephrol"},{"key":"859_CR14","first-page":"34A","volume":"27","author":"R Gansevoort","year":"2016","unstructured":"Gansevoort R, van Gastel M, Chapman A, Copeptin BJ. A surrogate for vasopressin, predicts disease progression and tolvaptan treatment efficacy in ADPKD. results of the TEMPO 3 4 trial. J Am Soc Nephrol. 2016;27:34A.","journal-title":"J Am Soc Nephrol"},{"key":"859_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.kint.2018.11.044","volume":"96","author":"RT Gansevoort","year":"2019","unstructured":"Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, et al. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019;96:159\u201369.","journal-title":"Kidney Int"},{"key":"859_CR16","doi-asserted-by":"publisher","first-page":"F361","DOI":"10.1152\/ajprenal.00070.2022","volume":"323","author":"T Masuda","year":"2022","unstructured":"Masuda T, Ohara K, Vallon V, Nagata D. SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats. Am J Physiol Renal Physiol. 2022;323:F361\u20139.","journal-title":"Am J Physiol Renal Physiol"},{"key":"859_CR17","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.199","volume":"84","author":"X Wang","year":"2013","unstructured":"Wang X, Zhang S, Liu Y, Spichtig D, Kapoor S, Koepsell H, et al. Targeting of sodium\u2013glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in han:SPRD rats. Kidney Int. 2013;84:962\u20138.","journal-title":"Kidney Int"},{"key":"859_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125603","volume":"10","author":"S Kapoor","year":"2015","unstructured":"Kapoor S, Rodriguez D, Riwanto M, Edenhofer I, Segerer S, Mitchell K, et al. Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats. PLoS\u00a0One. 2015;10: e0125603.","journal-title":"PLoS\u00a0One"},{"key":"859_CR19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2215\/CJN.09380822","volume":"18","author":"BF Palmer","year":"2023","unstructured":"Palmer BF, Clegg DJ. Kidney-protective effects of SGLT2 inhibitors. Clin J Am Soc Nephrol. 2023;18:279\u201389.","journal-title":"Clin J Am Soc Nephrol"},{"key":"859_CR20","doi-asserted-by":"publisher","first-page":"103697","DOI":"10.1016\/j.isci.2021.103697","volume":"25","author":"K Hopp","year":"2022","unstructured":"Hopp K, Catenacci VA, Dwivedi N, Kline TL, Wang W, You Z, et al. Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. iScience. 2022;25:103697.","journal-title":"iScience."},{"key":"859_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1681\/ASN.2017070819","volume":"29","author":"KL Nowak","year":"2018","unstructured":"Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, et al. Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2018;29:571\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"859_CR22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s10157-020-01856-1","volume":"24","author":"Y Ushio","year":"2020","unstructured":"Ushio Y, Kataoka H, Sato M, Manabe S, Watanabe S, Akihisa T, et al. Association between anemia and renal prognosis in autosomal dominant polycystic kidney disease: a retrospective study. Clin Exp Nephrol. 2020;24:500\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"859_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","volume":"77","author":"M Packer","year":"2021","unstructured":"Packer M. Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics. Am J Kidney Dis. 2021;77:280\u20136.","journal-title":"Am J Kidney Dis"},{"key":"859_CR24","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000362","author":"M Packer","year":"2023","unstructured":"Packer M. Alleviation of anemia by SGLT2 inhibitors in patients with CKD: mechanisms and results of long-term placebo-controlled trials. Clin J Am Soc Nephrol. 2023. https:\/\/doi.org\/10.2215\/CJN.0000000000000362.","journal-title":"Clin J Am Soc Nephrol"},{"key":"859_CR25","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.kint.2018.06.008","volume":"94","author":"A Kraus","year":"2018","unstructured":"Kraus A, Peters DJM, Klanke B, Weidemann A, Willam C, Schley G, et al. HIF-1\u03b1 promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease. Kidney Int. 2018;94:887\u201399.","journal-title":"Kidney Int"},{"key":"859_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/j.ajkd.2017.08.017","volume":"71","author":"A Srivastava","year":"2018","unstructured":"Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis. 2018;71:362\u201370.","journal-title":"Am J Kidney Dis"},{"key":"859_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2174\/1573402116666200817113125","volume":"17","author":"GM Brosnahan","year":"2021","unstructured":"Brosnahan GM, You Z, Wang W, Gitomer BY, Chonchol M. Serum uric acid and progression of autosomal dominant polycystic kidney disease: results from the HALT PKD trials. Curr Hypertens Rev. 2021;17:228\u201337.","journal-title":"Curr Hypertens Rev"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-024-00859-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-024-00859-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-024-00859-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T13:04:44Z","timestamp":1731589484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-024-00859-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1007\/s13730-024-00859-1","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The remaining author has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Due to the nature of a case report, ethics approval was not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}